University Hospitals Harrington Heart & Vascular Institute is the first site in the state of Ohio to clinically administer the FDA-approved Flyrcado(tm) (flurpiridaz F 18) injection to patients with known or suspected coronary artery disease.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
